Zoetis has launched UlcerGold (omeprazole) for the treatment - and prevention of recurrence - of gastric ulcers in horses and foals, presented in a syringe suitable for foals from four weeks of age and horses from 70 to 700kg.
Equine Gastric Ulceration Syndrome (EGUS) is a serious and common condition affecting horses and foals.2,3 Approximately 90% of racehorses, 60% of performance horses, 37% of leisure horses and 50% of foals have been shown to be affected.2,4,5 The condition is associated with injury to the mucosa of the oesophagus, stomach and duodenum, with prolonged exposure to gastric acid thought to be the primary cause.2,3 Risk factors include stress, intense exercise, a high-grain diet, intermittent feeding and illness.2,3 EGUS can have a profound impact on a horse's condition and performance and can ultimately be life threatening, especially in foals.3,5 It is a challenging condition to diagnose as the clinical signs are often vague and not always present.3 Gastroscopy is the only method currently available for a definitive diagnosis and treatment is usually based on acid suppressive therapy to allow ulcer healing.2
UlcerGold is indicated to treat and prevent the recurrence of gastric ulcers in horses, administered once-daily for 28 consecutive days at the full dose of 4mg/kg bodyweight followed by the reduced dose of 1mg/kg bodyweight for a further 28 days.1 It contains omeprazole, a proton pump inhibitor that suppresses gastric acid secretion.1,2 One syringe contains enough UlcerGold for a horse weighing up to 700kg. It can be used for foals as young as four weeks of age that weigh over 70kg and for breeding stallions.
Zoetis says UlcerGold is supported by a comprehensive gastroscope training programme, pricing model, client support and communications plan to ensure that it is a strong asset to veterinary businesses.
Penny McCann, Equine Product Manager, Zoetis UK Ltd, said: "UlcerGold is an exciting addition to our equine POM-V portfolio. We have designed a training, education and business programme to help practices make sure they get the best from our new product, not only in terms of gastric ulceration treatment but also practice health."
References
The service will be available to veterinary practices that use more than £250/€300 of Royal Canin urinary diets per year.
The company has enlisted the support of an independent laboratory to carry out an infrared spectroscopy analysis of the stones, in order to make a quantitative and qualitative assessment of their composition. Royal Canin says that by appreciating the mineral-type in all layers, the best dietary recommendation can be made.
Lee Danks, Royal Canin’s Veterinary Scientific Support Manager, said: "Managing cat and dog urolithiasis can be challenging. This valuable service will improve practices’ diagnostic capacity, enabling a better understanding of a patient’s condition and a much more individualised approach to treatment and long-term prevention."
Royal Canin says there are many complex and interacting contributors to urinary stone formation1. Dietary modifications can influence urine pH, the concentration of minerals within the urine and most critically, urine turn-over through the bladder2. The many interactions between promotors and inhibitors of urolithiasis highlight just how critical a tailored nutritional approach can be to the long-term health of urinary patients.
Jurox says Alfaxan Multidose is the bioequivalent to unpreserved Alfaxan, however the preserved formulation reduces the risk of microbial contamination, providing repeatable and reliable anaesthesia.
Alfaxan Multidose is available in two presentations of 10ml and 20ml, with the 20ml presentation priced at an equivalent price per ml as the current 10ml Alfaxan unpreserved presentation.
Jurox says there has been unprecedented interest in the new product, with the company taking pre-orders for the 20ml presentation from 60 different accounts at BSAVA this year.
Richard Beckwith, country manager at Jurox, said: "The introduction of Alfaxan Multidose to our anaesthesia and analgesia portfolio ensures that Alfaxan is more versatile than ever.
"The Alfaxan range continues to provide greater certainty and control during anaesthetic procedures, contributing towards better patient stability and a stress-free experience for the team."
For more information, visit www.alfaxan.co.uk, contact your local Jurox technical sales representative, telephone the customer services team on 0800 500 3171 or e-mail: info@jurox.co.uk.
Outcome of temporary tracheostomy tube-placement following surgery for brachycephalic obstructive airway syndrome in 42 dogs1 was undertaken at Dick White Referrals, UK. A retrospective case series of dogs that had a temporary tracheostomy tube placed in the post-operative period following surgery for BOAS was obtained from the referral hospital.
Of the 42 dogs, 11 had a tracheotomy tube placed electively and 31 had one placed as an emergency. The overall postoperative complication rate in the study was 95%. The minor complication rate – defined as resulting in no observable compromise of the clinical status and/or self-limiting, such as a cough - was 71%. The major complication rate – defined as resulting in discernible harm to the patient, such as cyanosis and dyspnoea - was 83%. 41/42 dogs were classified as having successful tracheostomy tube management.
Marius Stordalen, lead author of the paper said: "Contrary to what had been previously thought, this manuscript shows that in an appropriate clinical setting, temporary tracheostomy tube placement following multi-level airway surgery for brachycephalic obstructive airway syndrome carries a good prognosis for the majority of patients."
Nick Jeffery, editor of JSAP added: "Whilst overall mortality rate was low following placement of a tracheostomy tube in the postoperative period, there was a high overall complication rate. This finding demonstrates the need for continuous monitoring and intensive care for patients following placement of tracheostomy tube.”
The full article can be found in the May issue of the Journal of Small Animal Practice which is free for BSAVA members. It can also be read online here: https://onlinelibrary.wiley.com/doi/10.1111/jsap.13127
Miss Padron Vega faced four charges. The first and second alleged that in February 2016, for the purposes of an application to the Food Standards Agency for a Certificate of Competence under the Welfare of Animals at the Time of Killing Regulations 2015, she backdated two separate veterinary witness certificates to 7 December 2015. The third charge alleged that her acts of backdating were misleading, dishonest and in breach of the RCVS Principles of Certification.
The fourth charge against Miss Padron Vega was that, between September 2015 and February 2016, she failed to fulfil her duties as an Official Veterinarian in respect of: failing to prepare herself for the implementation of the Welfare of Animals at the Time of Killing Regulations 2015; failing to have regard to the information provided to her by her employers about the regulations and their implementation; failing to take any steps to ensure that the two individuals for whom she had given veterinary certification were licensed to perform slaughter in accordance with the regulations; and failing to identify that two individuals were not licensed to slaughter in accordance with the regulations.
The Committee heard that the Welfare at the Time of Killing Regulations were introduced on 5 November 2015 which placed the responsibility on slaughtering operations not to permit animal welfare abuses and required certification by a veterinary witness regarding compliance.
The new regulations required existing slaughter licence holders to apply for a Certificate of Competence before midnight on 8 December 2015 or they would not be permitted to continue operating even with experienced operatives.
During the hearing, Ms Padron Vega admitted charges 1 and 2, admitted that she had been in breach of the Principles of Certification and admitted the fourth charge against her.
However, she denied she had backdated the certificates in a misleading or dishonest way, maintaining that she had done so by mistake.
In considering the facts of the case, however, the Committee rejected this argument and, taking into account that she had been responsible for veterinary certifications in the UK since 2001, found that her conduct was knowingly misleading and dishonest.
The Committee then went on to consider whether the charges she admitted and the charges found against her constituted serious professional misconduct, both individually and cumulatively.
The Committee found that all the charges amounted to serious professional misconduct.
In relation to charge 4 in particular Stuart Drummond, chairing the Committee and speaking on its behalf, said: "The Committee has found that the respondent failed to read even those emails which her employer sent to her which were marked ‘urgent’ or ‘OV importance high’. She must have known that her employers were directing attention to some new statutory scheme for she was provided with PowerPoint slides in that regard which she could read at any time of her convenience. The Committee has been driven to the conclusion that the respondent did not even bother to read those slides for, had she done so, she would have known that she needed to apprise herself of the requirements of the impending new statutory scheme.
"The respondent’s failings in this regard are little short of extraordinary, especially given her obligations as Lead OV for FAI Farms. The total abdication of her responsibility to understand the requirements of the Regulations governing the slaughterhouse operations constitutes, in the judgement of this Committee disgraceful conduct in a professional respect."
The Committee then went on to consider the aggravating and mitigating factors in the case. In terms of aggravating features the Committee noted a lack of insight into the gravity of her conduct, that her conduct undermined in the most serious way public confidence in veterinary certification, and that there were animal welfare implications on her conduct as a number of chickens had to be removed from the slaughterhouse and alternative arrangements made because an auditor from the Food Standards Agency found that it was not compliant.
In mitigation the Committee considered that, despite the potential risk of harm, there was no actual harm occasioned to animals, that Miss Padron Vega has had a long and otherwise unblemished career and no previous issues with the RCVS and that she had admitted some of the charges against her.
Stuart Drummond added: "Ultimately, the Committee was driven to the conclusion that the public’s desire to see the implementation of the highest certification standards in relation to activities which impact on animal welfare and public health, and which did not occur on 3 February 2016, must outweigh this particular veterinary surgeon’s desire and need to continue in practice. This is not a conclusion which the Committee has arrived at lightly. On the contrary, it has reached this decision because it has been driven to the conclusion that it would be failing in its public duty to protect the wider public interest in the maintenance of standards of honesty and right conduct in a member of the profession.
"It is, therefore, the conclusion and decision of this Committee that the only proper sanction that can be imposed in this case is that the respondent’s name should be removed from the Register and it directs the Registrar accordingly."
Miss Padron Vega has 28 days from being informed of the Committee’s decision to lodge an appeal with the Privy Council.
Zoetis says the new vaccine, which is also the first in Europe to be administered orally, offers increased comfort for dogs, and a smooth consultation room experience for both dog owners and veterinarians. It has a 12-month duration of immunity.
Dr. Eileen Ball, Global Veterinary Medical Lead for Companion Animal Infectious Diseases for Zoetis, said: "Versican Plus Bb Oral provides robust protection along with an innovative and smooth means of administration. The new oral delivery brings a more positive experience for dogs, owners and vets. We expect this new option for vaccination will lead to an increase in recommendations for Bordetella prevention, better vaccination compliance, and ultimately a healthier dog population.
"Nearly all dogs are at risk of CIRDC, and Bordetella is a common, but preventable pathogen. Adding Versican Plus Bb Oral to vaccination protocols offers CIRDC protection for dogs. Vets can propose this new vaccination to pet owners at an annual wellness visit in the knowledge that they will be creating a less stressful experience for the pet and owner."
Zoetis has set up The European Canine Infectious Respiratory Disease Advisory Board – made up of veterinary specialists from across Europe – to provide guidance and advice on the product’s launch.
Board member, Professor Emeritus Michael J. Day, University of Bristol, a consultant to Zoetis, said: "The CIRDC has a multifactorial pathogenesis, involving environmental and lifestyle factors and numerous potentially causative organisms. CIRDC is not just a cough picked up in kennels. It can be spread in any space occupied by multiple dogs, including grooming parlours, dog day care establishments or dog parks. The pathogens have not disappeared over time and CIRDC is prevalent throughout Europe, with Bordetella bronchiseptica remaining a commonly identified agent in infected dogs.
"I think it is exciting for European veterinarians now to have another option in the way they deliver non-core Bordetella protection. There will be different situations depending on circumstances in which either an oral, intranasal, or injectable route of administration will be most appropriate."
Zoetis says Versican Plus Bb Oral will rolled out across Europe from November 2019 to October 2020.
The company says that the effervescent tablet presentation was designed to significantly improve vaccination practices for poultry producers while maintaining reliable virus protection.
Boehringer says this dispensing form reduces the risk of stock solution contamination and, when compared to glass vials, the small blister packs make vaccine management safer for operators, take up less room in the fridge and reduce packaging waste by 90%.
HatchPak IB H120 NeO will be available shortly in packs of 10 tablets of 1000 doses or 10 tablets of 2000 doses.
Callum Blair, Boehringer Ingelheim Avian and Swine Brand Manager, said: "The addition of HatchPak IB H120 NeO to our NeO product portfolio is evidence of our continued investment in the poultry sector."
The online risk checker, which is available at www.parassess.co.uk, asks pet owners a series of questions to assess their dog's risk from fleas, ticks, lungworm roundworm and tapeworm.
The test, which has been developed with parasitologists, takes a few minutes and appears to produce sensible results (not every test produces a "Danger, high risk, emergency, get to your vet NOW" result, as you might expect if this had been entirely produced bv the marketing department).
The subsequent report can then be shared with the vet to review it and make a treatment decision.
Being online, the test can be taken on a smartphone whilst in the practice waiting room, or on tablet or computer at home.
It might be worth sharing the test with your clients by email or social media, inviting them to book an appointment if their results suggest it is necessary.
To that end, Boehringer Ingelheim has produced a range of communication materials, such as waiting room displays and digital content for web, email, SMS, and social media.
For more information, contact your local Boehringer Ingelheim territory manager or phone 01344 746957 (UK) or 01 291 3985 (Ireland).
Fitzpatrick Referrals has carried out a world-first procedure in which an American Bulldog was fitted with a prosthetic hip and femur with a special in-growth attachment which effectively re-attaches the tendons and muscles to the artificial limb.
The procedure took place after 8 year old Roly was diagnosed with cancer in his rear hind leg earlier this year. It involved a highly complex two-hour operation, during which Dr Noel Fitzpatrick, a neuro-orthopaedic veterinary surgeon, replaced the cancerous femur bone and hip joint with a specially constructed artificial prosthesis, while re-attaching the musculature and realigning the relative position of the joint to restore perfect movement to the dog.
The prosthesis was designed through a collaboration between Professor Gordon Blunn, Head of the Centre for Bio-Medical Engineering at UCL's Institute of Orthopaedics and Musculoskeletal Science; veterinary surgeon Noel Fitzpatrick and Jay Meswania from specialist implant manufacturer OrthoFitz.
Professor Blunn said: "What is significant about the design is the way in which it sandwiches tissue and metal together overlaying the gluteal muscles onto the top of the endoprosthetic femur - alternating tendon, synthetic Dacron mesh, tendon, synthetic Dacron mesh, tendon and finally trabecular metal - which has a honeycomb surface resembling a series of small chambers. In this way, the hope is that the Sharpeys fibres which attach tendons of muscles to the bone will grow into the trabecular metal surface and permanently adhere to it."
"This truly remarkable achievement was made possible through the convergence of biomechanics, biology and surgical innovation," said Noel Fitzpatrick. "We tapped into the evidence provided by the CT and MRI scanners we have in place at the practice, so that the data collected about Roly during clinical diagnosis was used to design and construct an artificial femur which exactly mirrored his original limb. It has been constructed rather like a telescope - one section fitting inside the adjoining section, so that we get maximum flexibility and traction during motion."
Noel added: "Hip replacement is common here. We do more than 50 a year, on animals as small as a cat or a Chihuahua. But this hip replacement was special, and to my knowledge, the first of its kind in the world. It's important though to emphasise that this technology must only be employed when it is in the best interests of the individual patient. It's not enough to be able to do something; it must be done for the right reason in every case without exception. It must be ethically right. It's also important to emphasise that Roly will probably not live for a normal lifetime because bone cancer generally spreads to the lungs over time in spite of chemotherapy. However, this technology is equally applicable for dogs and cats affected by trauma who will likely live longer. My job is to look after my patients as best I can and to be honest with their guardians and give them options. What I do is provide pain free functional quality of life for as long as my patient is alive. That's important and that's special, but the decision must remain with each and every individual animal owner".
According to the team, this development also has potentialy life-changing implications for human patients such as motorcycle accident victims, where a key challenge to recovery may be successfully re-attaching the kneecap tendon onto the top of the tibia in the lower leg, and injured sports players with ruptured repairing ruptured tendons.
Click here to view the x-rays of this case in the VetSurgeon Gallery.
Fiproclear Combo, which contains fipronil and S-methoprene, is licensed for use on cats and dogs and can also be used to treat and prevent fleas and ticks on ferrets.
Norbrook says the new product provides effective protection from new flea infestations for up to eight weeks on dogs and four weeks on cats, while protecting against certain ticks for up to four weeks on dogs, and two weeks on cats.
Monica Whistler, Norbrook Marketing Product Manager, said: "With its triple-action approach, Fiproclear Combo kills adult fleas, ticks and biting lice. The addition of S-methoprene to the already-trusted ingredient fipronil, breaks the flea life cycle in the home by ensuring that any eggs laid by the fleas, which have come into contact with the product are infertile, and by preventing development of flea larvae within a pet’s surroundings.
"Adult fleas on pets are killed within 24 hours whilst newly arrived ticks are killed within 48 hours of attachment – before the main risk period of disease transfer. Ticks rank second only to mosquitoes as insects that spread infectious diseases to both pets and people1; the most common of which is Lyme disease."
Norbrook highlights research which showed almost a third of cats suffered from ectoparasites2, while around one in every three dogs are affected by ticks3, and that many traditional treatments do not help break the flea life cycle in the home.
Monica added: "Typically, by the time an owner notices a flea problem, an infestation has already been present for up to two months. At that point the visible adult fleas on the pet are only part of the problem, with 95% of the parasites already living in the home itself as eggs, larvae and pupae."
Virbac Animal Health has announced that its medical castration implant Suprelorin 9.4mg has received a marketing authorisation for use in ferrets.
The neutering of male ferrets (hobs) is recommended to suppress fertility, decrease odour and reduce territorial aggressive behaviour and urinary marking¹. According to Virbac, Suprelorin offers temporary sterilisation but without the need for surgery, and its use prevents the high Luteinizing hormone (LH)/Follicle-stimulating hormone (FSH) levels which occur following surgery and which can play a role in the development of hyperadrenocorticism².
Suprelorin is a slow-release implant containing the gonadotropin-releasing hormone (GnRH) agonist deslorelin. Once injected under the skin of healthy, sexually mature and entire ferrets, the continuous low release of deslorelin from the implant causes an interruption of the HPA circuit, leading to a reduction in LH/ FSH levels and therefore testosterone production. This results in a reduction of libido, spermatogenesis and testicle size.
The implant lasts for up to four years, at which stage the ferret can be re-implanted to maintain the effect.
Chris Geddes MRCVS, Virbac Product Manager, said: "For owners looking for a surgery-free route to the castration of male ferrets and the problems it can cause, Suprelorin provides a simple and effective alternative."
Suprelorin 4.7mg has been available for use in dogs since 2008. Suprelorin 9.4mg was launched in 2011.
For further information, please contact your Territory Manager or call Head Office on 01359 243243.
References:
Remote consultations and prescribing have been the subject of much debate in the profession of late. A motion to conduct a trial of prescribing without a physical examination was considered by the RCVS Council in November, when a large number of serious concerns were raised.
However, none of those concerns related to the provision of remote consulting services for existing clients with animals who are already under the care of the veterinary surgeon. That's where systems like this could add real value to the service offered by veterinary practices.
George Kyriacou, Director at VVG said: "Telemedicine is happening, and it’s happening in a big way. Virtual consultations are becoming more and more popular with pet owners who are not really sure if they need to see a vet and would simply like some reassurance.
"An option to have a qualified vet in your pocket at anytime of the day is attractive. However, the option to have a convenient consultation with your own trusted vet is the holy grail."
The system allows those practices who wish to charge for online consults to take payment online. Some, however, offer free consultations, in particular post-op, because it saves everyone time.
VVG points out that the system can also be used to deliver nursing consultations, too.
Simon Power, Commercial Manager at Vets One referrals in Crimplesham, Norfolk said: "Since adopting the system we have had a number of post-op and medication reviews virtually; it not only saves us a consulting room but also allows our clients to have the expert advice our team provide from the comfort of their own home."
VVG costs £249 to set up, plus from £59 per month thereafter, per practice.
For more information, contact George Kyriacou at George@thevvg.com or call 01842558022.
The company says VeggieDent Zen provides the same dental benefits as VeggieDent FR3SH Dental Chews, but also includes L-theanine.
L-theanine is an amino acid which Virbac says is known to positively influence GABA levels in the brain to help reduce anxiety and increase mental focus. According to the company, one VeggieDent Zen chew daily can help to calm and reduce anxiety in dogs whilst also providing regular oral care.
VeggieDent Zen is free from GMO corn, wheat, gluten and meat, and contains no colourants or artificial ingredients. The new chews also hold the Veterinary Oral Health Council (VOHC) seal for tartar control.
Claire Lewis, Product Manager at Virbac said: "Dental chews are a great way for pet owners to provide passive dental care at home. With VeggieDent Zen we are pleased to be able to offer pet owners a convenient, multi-functional approach to supporting their pet’s health and well-being."
VeggieDent Zen comes in 4 chew sizes (Extra-Small, Small, Medium & Large) and is available from the veterinary wholesalers now.
For information on VeggieDent Zen, contact your Virbac Territory Manager.
BVA President Sean Wensley said: "The UK's decision to leave the European Union will have a significant impact on matters of interest to the veterinary profession, particularly in relation to regulation, education, and workforce planning, but also in terms of animal welfare, research, surveillance, and animal movements.
"BVA will work hard to ensure the voice of the veterinary profession is heard during the negotiation and discussions that will now begin, in order to secure the best possible outcomes for our profession and for animal health and welfare in the UK. The Vet Futures report provides an excellent summary of issues we need to consider in those discussions, and the Vet Futures Action Plan, due to be launched at the Vet Futures Summit on 4 July, outlines key initiatives that we need to take forward, albeit with revised timelines while the full impact of Brexit is determined.
"BVA will retain an outward looking and inclusive perspective through our relationships with international partners, including the Federation of Veterinarians for Europe (FVE), Commonwealth Veterinary Association (CVA) and World Veterinary Association (WVA) to ensure the UK veterinary profession continues to influence and engage on cross border issues such as disease surveillance, veterinary medicines and antimicrobial resistance."
The new briefing will summarise the latest veterinary innovations, resources and research which are of practical value to vets in practice. In other words, only what you strictly need to know.
Need to Know content will be curated by three practising veterinary surgeons: Liz Barton MRCVS (Small Animal, pictured right), Aoife Byrne MRCVS (Equine), and Rachel Tennant MRCVS (Farm Animal). It replaces InDigestion, VetSurgeon.org’s previous monthly newsletter which only linked to the most popular content on the site itself. By contrast, Need to Know summarises developments from all sources.
VetSurgeon.org Editor Arlo Guthrie said: "In these days of information overload, our aim here is to provide busy veterinary surgeons with a really succinct summary of anything that really matters, wherever it comes from."
Need to Know is the result of a new partnership between VetSurgeon.org and Vetsnet, a veterinary wellbeing resource hub set up by Liz to support her colleagues in the profession, and the bulk of any additional advertising revenue generated by the initiative will be ploughed back into Vetsnet.
Arlo added: "Since VetSurgeon launched back in 2008, content has been entirely curated by me. I like to think that has worked reasonably well. Still, having practising veterinary surgeons involved editorially is a big step forward in making sure our content is always useful and relevant."
Anyone subscribed to receive emails from VetSurgeon.org on registration will automatically receive Need To Know.
If you have subscribed, but are NOT receiving emails from VetSurgeon.org, you usually need to log into your email account online and move emails from VetSurgeon.org from your spam or junk folder into your inbox. Some email providers (notably Hotmail) also allow you to ‘whitelist’ emails from certain people and organisations. In that case, add 'vetsurgeon.org' to your whitelist.
If you have unsubscribed from emails from vetsurgeon.org in the past and now want to resubscribe, email support@vetsurgeon.org and we’ll remove you from the exclusion list.
First, the practice carried out an infection control audit to ensure its protocols were robust.
The audit covered the cleaning of clinical areas, non-clinical areas (including offices, reception desks, kltchens and bathrooms), and the personal hygiene of staff members (including hand hygiene and work wear).
Using using the Nationwide Laboratory practice cleanliness screening programme, Rosemullion then conducted environmental swabbing of 10 clinical and non-clinical areas around the practice, including theatre tables, kennels, telephones and door handles, to review contamination levels.
Results showed varying levels of bacterial contamination in both clinical and non-clinical areas.
Finally, Rosemullion assessed personal hygiene and the potential for cross-contamination between patients, colleagues and the environment.
Staff were asked to complete an anonymous ‘Hygiene Self-assessment Questionnaire’ which covered ten areas, including; disinfecting hands; wearing gloves, scrubs with short sleeves and dedicated work shoes, and changing into uniforms when arriving at work.
Amongst clinical staff, there was a 66.75% compliance.
The team then discussed the results, consulted a lab microbiologist and formulated an improvement plan, which included updating the practice cleaning processes (including the cleaning of new touch points), introducing new colleague uniform rules (including changing into uniform upon arrival at work), improving hand hygiene (including providing hand gels for all colleagues) and using sanitising wipes in all office areas.
One month after the policy revisions, swab tests were repeated. They found no bacterial growth in any of the 10 previously swabbed areas.
After two months the colleague questionnaire was run again.
It found clinical colleague compliance over eight personal hygiene indicators had jumped from 66.75% to 92.5% compliance.Abi Redfearn, Senior Veterinary Nurse at Rosemullion, said: “When we opened in 2021, we were keen to monitor our infection control - as part of providing a hospital level of care under the RCVS Practice Standards Scheme.
"With around 100 colleagues and hundreds of patients passing through our doors every week, we are an extremely busy practice – so infection control is paramount in maintaining high clinical standards.“By updating our protocols and taking simple steps - such as providing sanitising materials in high-touch areas – we’ve significantly decreased the risk of environmental contamination.
"Our project is now being used as an example to encourage other practices.”
The company’s NEMO Cardiac Health Screening test detects heart disease using AI to analyse microRNAs - biomarkers that manage the immune system and its responses and act as regulators for disease progression or resolution.
MI:RNA says the new test, which can be taken from blood or urine samples, will help vets diagnose and monitor disease progression more effectively and give cats and dogs with heart disease 18 months more life.
Eve Hanks, CEO and founder of MI:RNA (pictured) said: “The use of precision medicine in veterinary diagnostics will help pet owners and breeders alike to ascertain where to direct their efforts and finances accordingly.
"There is massive potential to use this technology to help breeds who have real problems with heart and other diseases, and will consequently help owners and breeders to identify affected animals more quickly.
Professor Joanna Dukes-McEwan, Head of the Cardiology Service at the University of Liverpool said: "From our cardiac investigations, we knew exactly the underlying heart disease and the severity of this, so our data was used as a training set for the MI:RNA panel analysis.
"We have previously collected samples from dogs with myxomatous mitral valve disease and are currently collecting samples from cats with hypertrophic cardiomyopathy.
“I think the MI:RNA panels are most useful for vets in primary care practice to identify and confirm the severity of underlying cardiac disease in their patients.
"A simple blood test which could confirm that the cause of a heart murmur is MVD, and also indicate its severity, and whether the patient would benefit from treatment would be really helpful for primary care vets in practice.
"They might indicate which patients may benefit from referral, or indicate when a specific treatment is indicated.
"Future research with miRNA panels may also indicate novel pathways in progression of disease which might increase our understanding of the disease, or novel therapeutic options.”
Pill Assist Cat is a soft treat pouch into which you insert a tablet, mould the pouch around the tablet and then feed to the cat.
Royal Canin says that in its tests, tablets were administered to cats successfully in 91% of cases using Pill Assist, which is not far off the 97% achieved with Pill Assist Dog which was launched earlier this year.
Erin Carr, Veterinary Marketing Executive at Royal Canin, said: "It’s an honour to be recognised by such an important industry body.
"Pill Assist Cat is set to launch next year. As with our Pill Assist Dog products, the aim is to make a real difference to pet’s health and wellbeing by turning pill time into a positive experience for both the pet and the owner."
The article points towards the corporatisation of the profession, with 51% of practices now owned by private equity groups and 67% belonging to a group of three practices or more, as the main driver for an increase in vets' fees of over twice the rate of inflation between 2015 and 2020.
However, what the article focuses on, which is the issue of complex and very expensive treatments for pets, is a multifactorial problem which cannot be entirely blamed on corporatisation.
At its heart lie advances in science which now allow vets to offer ever more complex treatments and diagnostics which, when used in human medicine to prolong a human life might sometimes seem expensive, but when used to prolong the life of a dog, can occasionally seem a bit bonkers.
Indeed the article does point towards over-treatment being partly driven by 'celebrity vets advocating increasingly complex surgeries'.
Then there's the fact that both parties to the transaction are often heavily invested in the idea of doing whatever can be done to save the dog: the pet owner, who has anthropomorphised their pet since they first collected it, and the vet, who's entire career has been dedicated to doing their best for the patient in their care.
Then of course there's the inflationary effect of insurance on treatment.
After all, if the animal is insured, why wouldn't you throw the kitchen sink at it?
Things are complicated by the difficulty in estimating the cost of veterinary treatment at the outset, when so much depends on the unknown outcome of diagnostic tests, the progression of disease and the success or failure of treatment. It's not like quoting for a new exhaust system.
There's also the inflationary effect of the increasingly litigious and socially litigious world we live in. It would be no surprise if veterinary surgeons have become more likely to test for everything, when the consequences of missing something is a soul-destroying trial by social media.
And finally, there's the subjective value of money.
Nevertheless, the Daily Mail has a point.
Selling any product or service is about meeting clients' and customers' needs.
If you keep increasing the price of your product range until all you can offer is a Rolls Royce, sooner or later you're going to price yourself out of the market.
One other lesson for the profession from that article: 'No comment' is not a good look for a caring profession.
Animals Count, which describes itself as a political party for people and animals, will launch its EU election manifesto on 24th May from 12 noon at the Kings Oak, Loughton, where it will be putting into practice one of its proposed policies: subsidised basic and emergency animal health care for animals. Animals Count President and veterinarian, Andrew Knight, will provide free dog consultations and animal health care advice for all companion animals.
Animals Count will contest the European Parliament elections, taking place on the 4th of June. It hopes to end farming with poor welfare consequences for animals, long distance live animal transport, all hunting for sport, and introduce an EU-wide subsidised basic animal health care system.
Animals Count Leader, Jasmijn de Boo MSc., said: "Concern for animals has long been a mainstream priority, yet remains poorly represented by most political parties. In several countries political parties for animals have formed to meet this need. The Dutch Party for the Animals from which we grew now has 20 elected representatives, including 2 MPs and one senator."
"The EU elections are particularly important for people and animals. Around half the EC budget is spent on agriculture. Given today's economic climate there's never been a better time to re-examine the massive expenditure of tax-payer money on farming methods known to be strongly associated with poor animal welfare and serious environmental damage."
Miss de Boo, 33, Alex Bourke, 47, Vice-chair of Animals Count and best-selling author of the 'Vegetarian Guides' book series, and Richard Deboo, 41, City professional and public speaker on animal issues, will contest the June EU elections in the Eastern region of the UK. Animals Count's ultimate goal is a world in which animals are not exploited, and are treated as sentient beings.
Merial has launched Merilym 3, the first Lyme disease vaccine available in the UK.
Lyme disease is the most common vector-borne disease in Europe and there has been an increase of over 300% in the number of reported human cases in the UK since 20011. Caused by infection with bacteria from the Borrelia burgdorferi group, the disease is transmitted by Ixodes spp. ticks.
Merial says the vaccine contains inactivated antigens from Borrelia burgdorferi sensu stricto, Borrelia afzelli and Borrelia garinii, so provides broad spectrum immunity against infection. Vaccination with Merilym 3 induces high levels of antibodies against a key bacterial antigen, which are ingested by the tick during blood feeding and subsequently bind to the bacteria in the tick gut, reducing the risk of transmission from the tick to the host.
For use in dogs, the vaccine can be administered to puppies from 12 weeks old, with a primary vaccination course of two injections, three weeks apart, followed by annual boosters. It is available in packs of 10 doses.
For more information, speak to your local Merial Territory Manager.
Reference
The independent practice, which was set up in 2010 by husband and wife team Richard and Sophie Aylett, will be a hard act to follow because not only did they achieve awards in all three areas for which they were eligible, but they were marked as "Outstanding" in all three.
For farm practices, the five possible awards are: Team and Professional Responsibility, Client Service, Advisory/Consultancy Service, Diagnostic Service and In-Patient Service. However, as an ambulatory first opinion farm animal practice, Meadows Farm Vets Ltd was only eligible for the first three awards.
Comments from the PSS Assessor included:
"Clinical governance was developing well in the practice. The recording of all surgeries in a file but also in an easy to see chart on the wall, colour coded re follow up was an excellent idea."
"Infection control & biosecurity were taken very seriously and all vehicles were immaculately clean & tidy."
"There was great support provided to new graduates and a comprehensive induction for new team members."
"The resources for farmers including written reports, training meetings, general meetings and comprehensive monthly newsletters were the best I have seen in a farm practice."
"The use and monitoring of a surgical checklist for all surgical procedures was impressive."
Practice Principal Sophie Aylett said: "We are extremely proud to have been recognised by the Royal College for our modern and innovative approach to farm practice. It has been a real team effort in working towards these Awards and we are very excited to be the first farm animal practice to have achieved all three Awards.
"To be marked as “Outstanding” in all three areas is testament to the great team of competent, confident and content vets and staff who are Meadows Farm Vets Ltd."
The acquisition of Jurox brings Zoetis a valuable animal health portfolio, including Alfaxan, a leading anaesthetic product for companion animals and high-quality local R&D and manufacturing operations in Australia.
Stephanie Armstrong, Senior Vice President and Cluster Lead UK, BeNeLuX, Nordics & Ireland, said: “We are grateful to the O’Brien family for entrusting the future of this family-owned business to Zoetis.
"Jurox’s portfolio plays to the strengths of our core business and will be a complementary fit with the solutions we deliver to veterinary professionals, livestock producers and pet owners.
"With Zoetis’ global sales and regulatory expertise in more than 45 direct markets, we look forward to expanding the impact and reach of the entire Jurox portfolio here in the UK and Ireland.”
www.jurox.com
Vets4Pets has unveiled its latest national TV advertising campaign, which airs for the first time during Coronation Street on ITV tonight.
The 30-second commercial was shot at five different locations around the UK and features John Davies-Riand MRCVS Vet Partner at Vets4Pets Leeds and Sarah Scott Vet Nurse Partner at Vets4Pets Kettering.
The commercial is running nationally until 28th March and forms part of a national campaign offering owners of elderly pets a discounted £25 senior pet health check with a vet and a half price bag of senior pet food.
Gill Hammond, Head of Brand Marketing said: "It was really important to us when planning this new campaign that we feature our real partners, they are at the end of the day the core of our business and the faces that our clients see when they visit us. The offer itself, focusing on senior pets is testament to our partners' and their teams' commitment to on-going pet health care."
Lee Ashton, founder of Bugler Smith, the agency behind the new ad said: "Working with Vet4Pets on this project has been a really exciting process. Having got under the skin of the brief, and carried out some initial research within Vets4Pets practices nationwide, the overwhelming and consistent theme from everyone we spoke to, was how they have a real passion for pets and making every difference they can.
"This was key to our message, and we felt it was really important to use their best brand ambassadors (their own vets and veterinary nurses) to introduce the brand to the public, to really demonstrate in a straight forward way what makes them different to other vet practices, and we're really pleased with the outcome."
The new product, which is for the management of any condition where eye health is supported by providing additional moisture or lubrication, is suitable for dogs, cats, horses, rabbits and other animals.
Oculeze contains glycerine (0.8%), Aloe vera, chamomile and propolis extract, the latter of which contains polyphenols which Millpledge says have been shown to support corneal health by multiple mechanisms of action including modulation of the tear film and a reduction in inflammation, apoptosis and oxidative stress1.
Millpledge says Oculeze lasts longer on the ocular surface than non-lipid lubricants2 because it evaporates more slowly3.
This prolonged action means fewer administrations, which should help client compliance.
Oculeze comes in two sizes - a 10 millilitre bottle and a pack of ten resealable 0.6 millilitre vials, suitable for short term use and travel.
The 10ml bottle includes a filter, preserving sterility for up to three months after opening.
Oculeze is available direct from Millpledge or from your usual wholesaler.
https://millpledge.com/shop/oculeze
sales@millpledge.com